Clinical Guidelines

GSK’s RSV Vaccine Moves Closer to China Approval 

Regulatory filing for Arexvy has been accepted for review in China for adults aged 60 and older, where RSV affects millions each year

  • By

  • February 18, 2026

  • 2 min

Share

GSK's Arexvy, a recombinant and adjuvanted vaccine for respiratory syncytial virus (RSV), has received regulatory review acceptance from China's Center for Drug Evaluation for the prevention of lower respiratory tract disease in adults aged 60 and older. With RSV affecting over six million elderly adults in China annually and leading to more than 350,000 hospitalizations, this vaccine aims to address a significant health concern. Its development is backed by successful phase 3 clinical trial results, and if approved, Arexvy will be the first RSV vaccine available in China for this demographic, with a decision expected by 2027.

Original Source(s)

GSK’s RSV Vaccine Moves Closer to China Approval 

Regulatory filing for Arexvy has been accepted for review in China for adults aged 60 and older, where RSV affects millions each year

  • February 18, 2026

  • 2 min

Related Content

Bacterial Pseudaminic Acid Emerges as an Immune Target

Glycoproteomic mapping reveals pseudaminic acid as a shared feature across pathogenic bacteria 

  • February 18, 2026

  • 2 min
Hot Springs Yield Robust Enzymes for Molecular Diagnostics

Phage enzymes from extreme environments studied for diagnostic use

  • February 18, 2026

  • 2 min
Conjugative CRISPR System Cuts Resistance

Mobile gene drive-like platform spreads between bacteria and reduces ampicillin resistance by up to 5 logs while enabling cassette reversal